Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer

A PRISMA-compliant meta-analysis

Wen-wen Lv, PhD, Jin-jie Zhang, MS, Xiao-long Zhou, MS, Zheng Song, MS, Chuan-mei Wei, MS

Abstract

Background: Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) have been developed for targeted therapies in non-small-cell lung cancer (NSCLC); moreover, some drug-related toxic reactions among cancer patients have been reported. A meta-analysis of randomized controlled trials (RCTs) to define the incidence and the risk of grade ≥3 adverse events (AEs), serious and fatal AEs (SAEs and FAEs), with VEGFR-TKIs in advanced/metastatic NSCLC patients was performed.

Methods: A comprehensive literature search was conducted for the clinical trials published up to December 2017. Qualified studies allotted patients with advanced/metastatic NSCLC to receive either chemotherapy alone or in combination with VEGFR-TKIs. Data were extracted by 2 authors.

Results: Eighteen RCTs of VEGFR-TKIs plus chemotherapy, involving 8461 advanced NSCLC patients were included. The proportion of patients with grade ≥3 AEs was increased with the addition of VEGFR-TKIs (relative risk, 1.35; 95% confidence interval [CI] 1.19–1.52; incidence, 68.1% vs 50.1%; P < .001). The most common grade ≥3 AEs was neutropenia (24.9% vs 15.4%, P < .001). Addition of VEGFR-TKIs was also related to the increased risk of SAEs (relative risk, 1.34; 95% CI 1.14–1.56; incidence, 37.8% vs 27.9%; P < .001) and FAEs (relative risk, 2.16, 95% CI 1.47–3.19; incidence, 3.4% vs 1.8%). Subgroup analysis suggested there was no difference in the rates of SAEs and FAEs in the second-line settings. No evidence of bias was found between the literatures. The study was registered with PROSPERO (CRD42018099654).

Conclusions: In comparison with chemotherapy alone, the addition of VEGFR-TKIs in advanced NSCLC patients was related to the increased risk of grades ≥3 AEs, SAEs, and FAEs, especially in the first-line settings. Physicians should be aware of some specific grade ≥3 adverse effect, especially haematologic adverse events, and it is also necessary to monitor cancer patients receiving VEGFR-TKIs.

Abbreviations: AEs = adverse events, CI = confidence interval, CTCAE = Common Terminology Criteria for Adverse Events, FAEs = fatal adverse events, NSCLC = non-small cell lung cancer, PRISMA = Preferred Reporting Items for Systematic Review and Meta-Analysis, RCTs = randomized controlled trials, RR = relative risk, SAEs = serious adverse events, VEGFR-TKIs = vascular endothelial growth factor receptor-tyrosine kinase inhibitors.

Keywords: fatal adverse events, grade ≥3 adverse events, NSCLC, serious adverse events, VEGFR-TKIs
1. Introduction

It can be said that lung cancer is so common diagnosed malignant tumors throughout the world. Approximately 85% of lung cancer patients are infected with non-small-cell lung cancer (NSCLC). Of them, 65% to 75% patients had locally advanced or metastatic disease. At present, not only traditional chemotherapy, but also targeted therapy has been used to treat patients with NSCLC. Most people could benefit from targeted therapy with epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs), but will develop resistance and subsequent disease progression. KRAS mutations and other reasons reportedly were associated with resistance to EGFR-TKIs therapy. Inhibitors targeting KRAS, especially other important oncogenic signaling pathways, might be the options for patients with NSCLC.

Vascular endothelial growth factor receptor (VEGFR) is an important target for NSCLC. Several kinds of VEGFR-TKIs-targeted treatment of NSCLC have been developed by scientists, such as sorafenib, vandetanib, cediranib, and sunitinib. Although TKI may not have typical side effects on patients like other cytotoxic chemotherapeutic drugs, some drug-related toxicities have been found in cancer patients. Therefore, the concerns about the serious consequences or fatal adverse events (FAEs) with these target agents have been arisen.

In a recent meta-analysis, Hong et al demonstrated that the risk of death in NSCLC patients increased significantly (odds ratio: 2.37, P = .01) by using VEGFR-TKIs. Wang et al carried out a pooled analysis of the risk of grade ≥3 AEs of VEGFR-TKIs in advanced NSCLC patients. Both these meta-analyses-enrolled patients received VEGFR-TKIs or in combination with other drugs. A meta-analysis performed by Gu et al assessed the overall risk of severe AEs related to anti-VEGFR agents. Besides VEGFR-TKIs, VEGF antibody-based agents were also included in this meta-analysis. Grade ≥3 toxicity and the treatment-related deaths were comprehensively analyzed in a meta-analysis carried out by Li et al.

To our best knowledge, there is little systematic review and meta-analysis to summarize the incidence and risk of grade ≥3 toxicity, SAEs, and FAEs related to VEGFR-TKIs in combination with traditional chemotherapy, compared with traditional chemotherapy alone. Consequently, we performed this up-date meta-analysis of randomized controlled trial (RCTs). Additionally, the specific category of grade ≥3 AEs reported in these RCTs was simultaneously extracted.

2. Materials and methods

2.1. Study design

We conducted the meta-analysis according to the preferred reporting items for Systematic Reviews and Meta-Analysis. The project was prospectively registered in PROSPERO database, number CRD42018099654.

2.2. Search strategy and selection criteria

An extensive search was carried out in the following databases: PubMed, Embase, Web of Science, and the Cochrane library. The following keywords were searched: “non-small cell lung neoplasms,” “NSCLC,” “lung cancer,” “lung Carcinoma,” “sorafenib,” “BAY43-9006,” “nexavar,” “sunitinib,” “SU11248,” “sutent,” “pazopanib,” “GW786034,” “votrient,” “axitinib,” “AG-013736,” “regorafenib,” “cediranib,” “AZD2171,” “vandetanib,” “caprelsa,” “ZD6474,” “lapatinib,” “apatinib,” “lenvatinib,” “cabozantinib,” “tivozanib,” “AV-951,” “Lинфанib,” “ABT-869,” “angiogenesis inhibitor,” “VEGFR-TKIs,” and “randomized controlled trial.” References in the primary studies and relevant review articles were also viewed to find more publications. Only prospective RCTs published in English were searched.

Clinical trials that met the following condition were enrolled: patients with advanced NSCLC; subjects received chemotherapy or in combination with VEGFR-TKIs; reported the endpoints of interest; phase II or III RCTs comparing VEGFR-TKIs plus chemotherapy versus chemotherapy alone.

2.3. Data extraction and study validity assessment

Two investigators extracted data independently. The following messages were recorded: the name of the first author, the year of publication, study period, treatment line, treatment arms and VEGFRs dosage, number of patients included, median age, and the events of grade ≥3 AEs, SAEs, and FAEs.

The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) criteria, version 3 or 4.0 was used. The primary endpoint of this research was the incidence and relative risk of FAEs. The National Cancer Institute’s General Terminology Standard for Adverse Events defines the concept of FAEs as death from exposure to experimental drugs during clinical trials. We did not include FAEs related to disease progression. Secondary endpoints included grade ≥3 AEs and SAEs. The definition of SAEs is AEs causing death, life-threatening situation, hospitalization or prolongation of hospitalization, disability or permanent injury, congenital anomalies, or birth defects.

The quality evaluation of each study was based on the Cochrane Collaboration guidelines and “Risk of bias” tool. Disagreements between investigators were resolved by consensus.

2.4. Statistical analysis

The Cochrane Review Manager Version 5.3 and Stata/SE version 14.0 software (Stata, College Station, TX) were used to perform the statistical analysis. Data were summarized using relative risk (RR) with its 95% confidence interval (CI). The total incidence and RRs were counted by making the use of random-effects or fixed-effects models, relying on the heterogeneity of contained studies. The χ²-based Q statistic test was applied for the evaluation of the between-study heterogeneity, which was deemed to be significant when P_{heterogeneity} < 0.05 or I² > 50%. A 2-tailed P value <.05 was deemed to statistical significance. An estimate of potential publication bias was carried out making use of Begg and Egger tests.

3. Results

3.1. Trial characteristics and patients

As shown in Figure 1, 18 RCTs involving 8461 NSCLC patients were included for analysis, with 10 studies reporting the summary grade ≥3 AEs, 10 studies reporting SAEs, and 10 trials reporting treatment-related deaths. Their characteristics are listed in Table 1.
3.2. Risk of bias

The quality of the trial was generally good and the risk of bias was low (Fig. 2). Of the studies enrolled, 7 trials were considered to be with an excellent quality without bias. The most common problem is that there is no expression of randomization process and allocation concealment (selection bias), and the lack of blinding in the studies by Bellani et al., Dy et al., Heist et al., and Scagliotti et al. (performance bias and detection bias).

3.3. Grade ≥3 AEs

A total of 3007 patients from 10 treatment arms receiving VEGFR-TKIs could be used for analysis of summary incidence of grade ≥3 toxicity. Using a random-effects model, the total incidence of grade ≥3 AEs was determined to be 68.1% (95% CI 59.5%–76.7%) in VEGFR-TKIs group, compared with 50.1% (95% CI 38.2%–61.9%) in chemotherapy group.

A meta-analysis of RR for grade ≥3 AEs associated with VEGFR-TKIs was carried out. The pooled results indicated that the risk of grade ≥3 AEs was significantly increased with the application of VEGFR-TKIs (RR = 1.35, 95% CI 1.19–1.52, P < .001). As shown in Figure 3, subgroup analysis showed the increased grade ≥3 toxicity was still significant in both first-line (RR = 1.40, 95% CI 1.17–1.69, P < .001) and second-line settings (RR = 1.23, 95% CI 1.04–1.46, P = .02).

Specific grade ≥3 AEs reported in ≥5 studies or with a morbidity of >5% were assessed for further analysis. Neutropenia (24.9%, 95% CI 18.0%–31.7% vs 15.4%, 95% CI 10.3%–20.4%; P < .001) was the most common AE. As shown in Table 2, except for gastrointestinal events (nausea, vomiting, and constipation, decreased appetite), thromboembolic events, dyspnea, and peripheral neuropathy, other severe AEs showed significantly difference compared with control group. However, the risk of grade ≥3 anemia with VEGFR-TKIs was significantly lower than that in control group.

3.4. SAEs

A total of 6225 patients (3122 VEGFR-TKIs, 3103 controls) from 10 RCTs were available for the analysis of SAEs. The total incidence of SAEs was 37.8% (95% CI 30.2%–45.2%) in treatment group and 27.9% (95% CI 19.9%–35.9%) in control group by using a random-effects model. The risk of SAEs was significantly higher in the TKI combination therapy group, using a random model (RR = 1.34, 95% CI 1.14–1.56; P < .001). It was of interest to note the increased risk of SAEs was significant in the first-line treatment (RR = 1.52, 95% CI 1.36–1.71, P < .001, I² = 12%), but not in the second-line settings (RR = 1.01, 95% CI 0.90–1.13, P = .91, I² = 7%, Fig. 4).

Figure 1. Selection process for the randomized controlled trials included in the meta-analysis.
### Table 1
Characteristics of included randomized controlled trials.

| First author, year (ref) | Study design | Treatment line | Treatment arms | Number for analysis | Median age, y | Median PFS, mo | Median OS, mo |
|--------------------------|--------------|----------------|----------------|---------------------|---------------|----------------|---------------|
| Heymach et al, 2007[18]  | Phase II     | Second line    | Vandetanib 100 mg + docetaxel | 42 | 61 (30–76) | 4.7 | 13.1 |
| Heymach et al, 2008[19]  | Phase I      | First line     | Vandetanib 300 mg + docetaxel | 44 | 60 (29–82) | 4.2 | 7.9 |
|                         |              |                | Placebo + docetaxel | 41 | 58 (41–78) | 4.0 | 13.4 |
|                         |              |                | Vandetanib 300 mg + carboplatin/ paclitaxel Placebo + carboplatin/paclitaxel | 56 | 60 (36–70) | 6.0 | 10.2 |
| Goss et al, 2010[20]    | Phase II     | First line     | Cediranib 30 mg/day + docetaxel/carboplatin | 52 | 59 (42–83) | 5.8 | 12.6 |
|                         |              |                | Placebo + paclitaxel/carboplatin | 126 | 60 (36–77) | 5.6 | NM |
| Herbst et al, 2010[21]  | Phase II     | Second line    | Vandetanib 100 mg/day + docetaxel | 123 | 58 (39–81) | 5.0 | 10.6 |
|                         |              |                | Placebo + docetaxel | 689 | 59 (28–85) | 4.0 | 10.6 |
|                         |              |                | Vandetanib 100 mg/day + docetaxel | 690 | 59 (20–82) | 3.2 | 10.0 |
| Scaglotti et al, 2010[22] | Phase III   | Second line    | Sorafenib 400 mg twice a day + carboplatin/paclitaxel | 463 | 62 (34–86) | 4.6 | 10.7 |
|                         |              |                | Placebo + paclitaxel/carboplatin | 459 | 63 (34–82) | 5.4 | 10.6 |
|                         |              |                | Varnetinib 100 mg/day + paclitaxel | 273 | 60 (35–83) | 3.0 | 9.2 |
|                         |              |                | Placebo + pemetrexed | 385 | 59 (28–81) | 6.0 | 12.4 |
|                         |              |                | Sorafenib 400 mg twice a day + gemcitabine/cisplatin | 384 | 58 (22–77) | 5.5 | 12.5 |
|                         |              |                | Placebo + gemcitabine/cisplatin | 533 | 60 (23–87) | 5.6 | 13.0 |
|                         |              |                | Vandetanib 125 mg/day + paclitaxel/carboplatin | 539 | 60 (21–84) | 5.4 | 11.0 |
|                         |              |                | Placebo + paclitaxel/carboplatin | 58 | 65 (46–81) | 6.3 | 12 |
|                         |              |                | Vandetanib 100 mg + gemcitabine | 29 | 64 (45–82) | 4.5 | 9.9 |
|                         |              |                | Gemcitabine/carboplatin | 61 | 62 (40–75) | 6.2 | NM |
|                         |              |                | Placebo + paclitaxel | 34 | 64 (36–74) | 5.7 | |
|                         |              |                | Cediranib 30 mg/day + gemcitabine/carboplatin | 55 | 62 (30–77) | 6.0 | 17.0 |
|                         |              |                | Paclitaxel + gemcitabine | 55 | 59 (42–76) | 7.1 | 15.9 |
|                         |              |                | Axitinib 5 mg bid + pemetrexed/cisplatin | 61 | 75 (70–82) | 6.1 | 8.7 |
|                         |              |                | Varnetinib 100 mg/day + gemcitabine | 63 | 75 (70–84) | 5.6 | 10.2 |
|                         |              |                | Paclitaxel + gemcitabine | 151 | 63 (23–85) | 5.5 | 12.2 |
|                         |              |                | Placebo + gemcitabine/paclitaxel | 153 | 62 (36–77) | 5.5 | 12.1 |
|                         |              |                | Vandetanib 125 mg/day + paclitaxel/carboplatin | 181 | 62 (31–79) | 4.9 | 11.1 |
|                         |              |                | Placebo + paclitaxel/carboplatin | 173 | 59.5 (32–81) | 5.1 | 10.7 |
|                         |              |                | Paclitaxel + gemcitabine/cisplatin | 39 | 63 (38–84) | 4.7 | 6.7 |
|                         |              |                | Pemetrexed + vindesini 37.5 mg daily | 42 | 49 | 4.9 | 10.5 |
|                         |              |                | Placebo + pemetrexed | 652 | 60 (53–67) | 3.4 | 10.9 |
|                         |              |                | Cisplatin + pemetrexed | 655 | 60 (54–66) | 7.9 | |
|                         |              |                | Nintedanib 200 mg twice daily + docetaxel Placebo + docetaxel | 42 | 61.5 (35–79) | 8.3 | 11.4 |
|                         |              |                | Linifanib 7.5 mg + carboplatin/paclitaxel | 47 | 60 (43–79) | 7.3 | 13.0 |
|                         |              |                | Nintedanib 12.5 mg + carboplatin/paclitaxel | 47 | 61 (44–79) | 5.4 | 11.3 |
|                         |              |                | Placebo + pemetrexed | 347 | 60 (21–84) | 4.4 | 12.0 |
|                         |              |                | Placebo + pemetrexed | 357 | 59 (26–86) | 3.6 | 12.7 |

NM = not mentioned, OS = overall survival, PFS = progression-free survival.

### 3.5. FAEs

Ten trials were included for the analysis of FAEs. No FAEs occurred in 1 RCT.[18] There are 78 among 2108 patients who received VEGFR-TKIs and 33 in 1989 control patients experienced FAEs. Again, a random-effects model was applied. The incidence of FAEs was 3.4% (95% CI 1.9%–4.9%) in VEGFR-TKIs group, and 1.8% (95% CI 0.0%–3.3%) in chemotherapy group.

This pooled result of RR indicated that the risk of FAEs was significantly increased by adding VEGFR-TKIs (RR = 2.16, 95% CI 1.47–3.19, P < .001; Fig. 5). Subgroup analysis suggested a significant increase of risk in first-line (RR = 3.64, 95% CI 1.88–7.07, P < .001, I² = 0%), but not in the second-line settings (RR = 1.52, 95% CI 0.93–2.48, P = .09, I² = 16.9%), which was the same as the results of SAEs.

### 3.6. Sensitive analysis

Sensitivity analysis was performed to test the reliability and stability of pooled RRs by sequential omission of individual studies, to interpret heterogeneity in grade ≥3 AEs. The consequence showed that the significance estimate of pooled RRs was not influenced by deleting any single study (Table 3).[22–26,31–35]

### 3.7. Risk of bias across studies

No public bias was found between studies that reported SAEs by either the Begg or Egger tests, except for grade ≥3 AEs and FAEs. However, public bias almost disappeared stratified by line of chemotherapy (Table 4).

### 4. Discussion

Targeted therapies for cancer treatment are positive and negative, like coins. Patients often overestimate the benefits of treatment and ignore the side effects.[36] Thus, in the decision-making process of oncology clinic, the discussion of possible side effects should play an important role.
There have been some meta-analyses estimating toxicities with VEGFR inhibitors. However, specific meta-analysis assessing the SAEs and/or FAEs associated with VEGFR-TKIs in advanced NSCLC was very little. Additionally, it was worth to mention that only grade ≥3 AEs were mostly reported in these meta-analyses. Another important endpoint, SAEs, which can cause treatment interruption or discontinuation, even can cause hospitalizations, disabilities and deaths, should be a significant part of shared decision-making.\[37\] As far as we know, limited data are particularly focused on the SAEs related to VEGFR-TKIs in NSCLC. We therefore carried out this meta-analysis of RCTs to assess not only the incidence and RR of FAEs, but also grade ≥3 toxicities and SAEs of VEGFR-TKIs in advanced NSCLC patents.

First, this meta-analysis showed the risk of grade ≥3 toxicities was significantly increased compared with traditional chemotherapy agents (RR: 1.35, 95% CI 1.19–1.52, \( P < .001 \)). A subgroup analysis was carried out to explain the heterogeneity. The result suggested the incidence of grade ≥3 AEs was higher in VEGFR-TKIs group, either in first- or in the second-line treatment, which was consistent with the result of the previous study.\[10\]

Compared with cytotoxic chemotherapy, VEGFR-TKIs were historically deemed to have obviously nonoverlapping toxicities. Whereas, meta-analysis have exposed that TKIs were related to the addition of the risk of neutropenia,\[38\] thrombocytopenia,\[38\] cutaneous toxicities,\[39–42\] hypertension,\[43–46\] fatigue,\[47\] hemorrhage,\[48\] and arterial thrombotic event.\[49\] According to the current reported experimental results, some toxicities are indeed overlapping and additive (neutropenia, leukocytopenia, thrombocytopenia, rash, fatigue, diarrhea, hypertension, anorexia, mucositis, and hemorrhage events). Although the risk of neutropenia, thrombocytopenia, and leukocytopenia was higher with VEGFR-TKIs, high-grade anemia was not increased with VEGFR-TKIs in the previously reported meta-analyses.\[38,50,51\] Our results also indicated there is no addition of the danger of severe anemia with VEGFR-TKIs (RR: 0.75, 95% CI 0.57–0.98, \( P = .04 \)), and showed that VEGFR-TKIs may have a certain protective effect on anemia.\[52\]

Importantly, this meta-analysis showed VEGFR-TKIs combining with traditional chemotherapy are associated with increased rates of SAEs and FAEs in patients with advanced NSCLC. We surprisingly found that both of these associations were not statistically significant in the second-line settings (Figs. 3 and 4). The risk of SAEs associated with VEGFR-TKIs had only been reported in 2 meta-analyses.\[53,37\] Both of these 2 studies were not related about NSCLC. Our study is the first meta-analysis to report on SAEs with VEGFR-TKIs in advanced NSCLC patients. The pooled incidence of FAEs in patients receiving VEGFR-TKIs was 3.4% in this meta-analysis, nearly twice as high as for those patients in placebo/control groups at 1.8%. The risk of FAEs related to VEGFR-TKIs in cancer patients had been reported in 5 meta-analysis.\[54,55,7,56,57\] Subgroup analysis stratified by line of chemotherapy was not performed in any one of these studies, except one conducted by Li et al.\[10\] They found treatment-related deaths were significantly higher with the addition of VEGFR-TKIs to chemotherapy in advanced NSCLC patients (odds ratio 2.37, 95% CI 1.58–3.56; \( P < .0001 \)), and this increase was also significant in the second-line treatment (odds ratio 1.74, \( P = .03 \)). In their second-line subgroup analysis, deaths data from RCT performed by Herbst et al\[21\] was also included. In that RCT, 5 deaths in patients receiving vandetanib plus docetaxel were not definitely attributed to treatment protocol, which was therefore dropped in our study. In the first treatment line, VEGFR-TKIs were combined with platinum doublet...
chemotherapy. That might have led to serious toxicity reactions (SAEs, RR 1.52, \( P < .001 \); FAEs, RR 3.64, \( P < .001 \)), and may be the reason of the higher incidence of SAEs and FAEs in the first-line setting.

However, this meta-analysis has some limitations. First, this is a meta-analysis based on the study level. Second, patients treated with different VEGFR-TKIs were included, and the clinical heterogeneity might be increased among the trials, although subgroup analysis according to the treatment line was carried out. Additionally, heterogeneity can be found in the analysis of grade ≥3 AEs. Therefore, the random-effects model was applied to adjust for the heterogeneity. We also conducted a subgroup and sensitivity analysis for this endpoint. Ultimately, publication bias is likely to occur, even though no evidence of published bias has been found through Begg or Egger tests.

**Table 2**

Incidence and RR of specific severe adverse events in randomized controlled trials.

| Specific adverse outcome (grade ≥3) | No. of patients | VEGFR-TKIs, events/total | Controls, events/total | RR (95% CI) | \( P \) | \( \hat{\rho} \) (%) |
|------------------------------------|-----------------|--------------------------|------------------------|-------------|------|-----------|
| Neutropenia                        | 14              | 573/3140                 | 402/3071               | 1.34 (1.20–1.49) | <.001 | 41.5      |
| Rash                               | 8               | 91/1384                  | 131/1348              | 6.28 (3.66–10.78) | <.001 | 17.0      |
| Fatigue                            | 14              | 230/2938                 | 164/2873              | 1.35 (1.11–1.63) | .002  | 5.9       |
| Diarrhea                           | 16              | 232/4148                 | 81/4077               | 2.75 (2.16–3.52) | <.001 | 41.0      |
| Thrombocytopenia                   | 10              | 134/1904                 | 49/1946               | 2.63 (1.92–3.60) | <.001 | 34.6      |
| Dyspnea                            | 10              | 116/2260                 | 133/2239              | 0.87 (0.68–1.10) | .24   | 0         |
| Leukocytopenia                     | 4               | 133/1482                 | 100/1405              | 1.31 (1.02–1.67) | .03   | 44.1      |
| Hypertension                       | 13              | 123/2087                 | 25/5008               | 4.32 (2.89–6.47) | <.001 | 0         |
| Thromboembolic events*             | 8               | 77/2179                  | 76/2207               | 1.03 (0.76–1.39) | .87   | 0         |
| Anemia                             | 12              | 89/2959                  | 110/2899              | 0.75 (0.57–0.98) | .04   | 34.6      |
| Anorexia                           | 7               | 53/2103                  | 29/2134               | 1.81 (1.17–2.82) | .008  | 25.9      |
| Decreased appetite                 | 5               | 22/1296                  | 17/1274               | 1.24 (0.67–2.30) | .50   | 0         |
| peripheral neuropathy              | 5               | 20/1154                  | 25/1171               | 1.16 (0.70–1.99) | .54   | 0         |
| Nausea                             | 13              | 55/3400                  | 45/3365               | 1.15 (0.78–1.68) | .49   | 0         |
| Vomiting                           | 13              | 56/3847                  | 52/3866               | 1.07 (0.74–1.55) | .72   | 16.6      |
| Mucositis                          | 5               | 20/1964                  | 2/1961                | 5.68 (1.85–17.44) | .002  | 0         |
| Hemorrhage events†                 | 8               | 29/2413                  | 9/2403                | 2.99 (1.46–6.10) | .003  | 0         |
| Constipation                       | 8               | 7/2289                   | 8/2304                | 0.83 (0.34–2.04) | .68   | 0         |

CI = confidence interval, RR = relative risk, VEGFR-TKIs = vascular endothelial growth factor receptor-tyrosine kinase inhibitors.

*Thromboembolic events include arterial thromboembolic events, venous thromboembolic events, and pulmonary emboli.

†Hemorrhage events include hemoptysis, pulmonary hemorrhage, gastrointestinal hemorrhage, and nose hemorrhage.
5. Conclusions
This is a comprehensive meta-analysis that specifically evaluated the grade ≥3, serious and fatal toxicities of adding VEGFR-TKIs to chemotherapies in advanced NSCLC patients, and also the most reported specific grade ≥3 AEs. Our results show that the addition of VEGFR-TKIs to chemotherapies in NSCLC significantly increases grade ≥3 toxicity, SAEs, and FAEs compared with traditional chemotherapy alone, especially in the first treatment line. Monitoring AEs, especially haematologic AEs during VEGFR-TKIs therapy, is recommended.
Table 3
Sensitivity analysis of grade ≥3 AEs associated with VEGFR-TKIs versus control.

| First author, year | Remove | RR (95% CI) | p |
|-------------------|--------|-------------|---|
| Scagliotti et al, 2010[34] | ✓ | 1.29 (1.15–1.43) | 0.003 |
| de Boer et al, 2011[35] | ✓ | 1.36 (1.21–1.58) | 0.22 |
| Scagliotti et al, 2012[35] | ✓ | 1.37 (1.18–1.59) | 0.40 |
| Paz-Ares et al, 2012[36] | ✓ | 1.20 (1.16–1.45) | 0.87 |
| Dy et al, 2013[36] | ✓ | 1.39 (1.22–1.58) | 0.87 |
| Novello et al, 2014[37] | ✓ | 1.35 (1.18–1.54) | 0.87 |
| Heist et al, 2014[38] | ✓ | 1.30 (1.16–1.47) | 0.87 |
| Reck et al, 2014[39] | ✓ | 1.39 (1.20–1.60) | 0.87 |
| Ramalingam et al, 2015 7.5 mg[34] | ✓ | 1.34 (1.17–1.52) | 0.87 |
| Ramalingam et al, 2015 12.5 mg[34] | ✓ | 1.35 (1.19–1.54) | 0.87 |
| Hanna et al, 2016[35] | ✓ | 1.36 (1.18–1.57) | 0.87 |

FAEs = adverse events, SAEs = serious adverse events.

Table 4
Public bias Begg and Egger test (p value).

| Endpoint | Begg test | Egger test |
|----------|-----------|------------|
|          | Total studies | First line | Second line | Total studies | First line | Second line |
| Grade ≥3 AEs | 0.04 | 0.55 | 0.31 | 0.04 | 0.29 | 0.25 |
| SAEs      | 0.28 | 0.54 | 1.00 | 0.25 | 0.38 | 0.20 |
| FAEs      | 1.00 | 0.71 | 1.00 | 0.003 | 0.22 | NA |

AEs = adverse events, FAEs = fatal adverse events, NA = not available, SAEs = serious adverse events.

Author contributions
Conceptualization: Chuan-mei Wei.
Data curation: Wen-wen Lv, Jin-jie Zhang.
Formal analysis: Wen-wen Lv, Jin-jie Zhang, Xiao-long Zhou.
Funding acquisition: Wen-wen Lv, Jin-jie Zhang. Chuan-mei Wei.
Methodology: Wen-wen Lv, Jin-jie Zhang.
Project administration: Chuan-mei Wei.
Supervision: Zheng Song, Chuan-mei Wei.
Validation: Wen-wen Lv, Jin-jie Zhang, Zheng Song, Chuan-mei Wei.
Writing – original draft: Wen-wen Lv.
Writing – review & editing: Wen-wen Lv, Jin-jie Zhang, Xiao-long Zhou, Zheng Song, Chuan-mei Wei.

References
[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin 2014;64:9–29.
[2] Langer CJ, Besse B, Guallberto A, et al. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3511–20.
[3] Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer. Clin Cancer Res 2007;13:2890–6.
[4] Yu HA, Arcila ME, Hellmann MD, et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790 M mutations found by routine clinical molecular testing. Ann Oncol 2014;25:423–8.
[5] McCarthy MJ, Pagba CV, Prakash P, et al. Discovery of high-affinity noncovalent allosteric KRAS inhibitors that disrupt effector binding. ACS Omega 2019;4:2921–30.
[6] Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1999;49:407–24.
[7] Hong SD, Fang WF, Liang WH, et al. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trial. Onco Targets Ther 2014;7:1851–67.
[8] Wang S, Yang Z, Wang Z. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer? Oncotarget 2015;6:18206–23.
[9] Gu B, Gao WC, Chu HJ, et al. Adverse events risk associated with anti-VEGFR agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. Medicine 2016;95:48.
[10] Li BT, Barnes TA, Chan DL, et al. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: a meta-analysis of randomized trials. Lung Cancer 2016;102:21–7.
[11] Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097 doi:10.1371/journal.pmed.100.
[12] Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. National Institutes of Health National Cancer Institute; 2009.
[13] U.S. Food and Drug Administration. What is a serious adverse event? Available at: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm. (February 2016, date last accessed).
[14] Higgins J, Green S. Handbook for Systematic Reviews of Interventions Version 5.1. The Cochrane Collaboration, 2011, available at: www.cochrane-handbook.org.
[15] Zintaaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123–37.
[16] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
[17] Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
[18] Heymach JV, Johnson BS, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007;25:4270–7.
[19] Heymach JV, Paz-Ares L, Braud FD, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:4047–15.
[20] Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small cell lung cancer: NCIC Clinical Trials Group BR24 Study. J Clin Oncol 2010;28:49–55.
[21] Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619–26.

[22] Scagliotti G, Novello S, Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835–42.

[23] de Boer RH, Arrieta Ó, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29:1067–74.

[24] Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonquamous non-small-cell lung cancer. J Clin Oncol 2012;30:3084–92.

[25] Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012;30:2829–36.

[26] Dy GK, Mandrekar SJ, Nelson GD, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol 2013;8:79–88.

[27] Scagliotti GV, Felip E, Besse B, et al. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol 2013;8:1329–37.

[28] Belani CP, Yamamoto N, Bondarenko IM. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer 2014;14:290.

[29] Gridelli C, Novello S, Zilembo N, et al. Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. J Thorac Oncol 2014;9:733–7.

[30] Laurie SA, Solomon BJ, Seymour L, et al. Randomised, double-blind phase III trial. J Clin Oncol 2011;29:1067–74.

[31] Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in cancer patients treated with sorafenib: a systematic review and meta-analysis. Cancer Treat Rev 2013;39:818–30.

[32] Chu D, Lacouture ME, Weiner E, et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sorafenib in patients with renal cell and nonrenal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009;7:11–9.

[33] Zhang L, Zhou Q, Ma L, et al. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 2011;36:344–50.

[34] Rosen AC, Wu S, Damse A, et al. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:1125–33.

[35] Fischer A, Wu S, Ho AL, et al. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and metaanalysis. Invest New Drugs 2013;31:787–97.

[36] Zhu X, Stegoglobous K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sorafenib: systematic review and meta-analysis. Acta Oncol 2009;48:9–17.

[37] Qi WX, He AN, Shen Z, et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;76:348–57.

[38] Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Pharmacist 2013;75:919–30.

[39] Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013;27:601–11.

[40] Santoni M, Conti A, Massari F, et al. Treatment related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer 2015;136:1–0.

[41] Ye J, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sorafenib and sunitinib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10:967–74.

[42] Choueiri TK, Schutz FA, Ye J, et al. Risk of arterial thromboembolic events with sorafenib and sunitinib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280–5.

[43] Schutz FA, Je Y, Choueiri TK. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol 2011;80:291–300.

[44] Barni S, Cabiddu M, Guarneri P, et al. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715–24.

[45] Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793–800.

[46] Cao MH, Li FF, Wang Y, et al. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials. Invest New Drugs 2017;35:834–8.

[47] Schutz FA, Je Y, Richards CJ, et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012;30:871–7.

[48] Sivendran S, Liu Z, Portas LJ, et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat 2012;38:919–25.

[49] Zhang XJ, Zhang TY, Yu FF, et al. Risk of treatment-related mortality with sorafenib in patients with cancer. Asian Pac J Cancer Prev 2013;14:6681–6.

[50] Yang X, Pan X, Cheng X, et al. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials. Int J Clin Pharm 2015;37:1047–56.